This review was based on articles identified by a MEDLINE search with the terms āLewy bodyā, ādementiaā, and āParkinson's diseaseā as the main keywords or identified from the reference lists of relevant articles, review papers, and book chapters. Articles for citation were chosen for their historical value, importance, ease of access, and timeliness based on the expert knowledge of the delegates.
ReviewDementia with Lewy bodies
Section snippets
Diagnostic concepts
DLB and PDD are clinically defined syndromes; although consensus clinical criteria have been validated for DLB,2 no formal clinical diagnostic criteria have been proposed or validated for PDD (the subject of a recent comprehensive review in this journal).11 An arbitrary ā1-year ruleā has until now been used to separate DLB from PDD; onset of dementia within 12 months of parkinsonism qualifies as DLB and more than 12 months of parkinsonism before dementia as PDD. The limitations of this approach
Clinical and pathological criteria for DLB
There is some convergence of agreement on the core clinical features of DLB, which are fluctuating cognitive impairment, recurrent visual hallucinations, and parkinsonism.17 The clinical distinctions between DLB and Alzheimer's disease are increasingly recognised (panel).2 The presence of Alzheimer's pathology in DLB modifies the clinical presentation, with the lower rate of visual hallucinations and parkinsonism making such cases harder to differentiate clinically.18 The specificity and
Epidemiology
In population-based clinical studies of people aged 65 years or older, the prevalences of DLB and PDD were reported to be 0Ā·7% and 0Ā·3%, respectively, which suggests that each could account for up to 10% of all dementia cases, a proportion consistent with DLB rates of 10ā15% from hospital-based autopsy series. A community study of people aged over 85 years found that 5Ā·0% met consensus criteria for DLB (3Ā·3% probable, 1Ā·7% possible) representing 22% of all demented cases,30 similar to other
Clinical phenomenology of DLB Cognitive
Cognitive impairment is the presenting feature of DLB in most, but not all, cases. The disorder typically presents with recurrent episodes of confusion on a background of progressive deterioration. Patients with DLB show a combination of cortical and subcortical neuropsychological impairments34, 35 with substantial attentional deficits and prominent frontosubcortical and visuospatial dysfunction36 that help to differentiate this disorder from Alzheimer's disease.37, 38 Patients with DLB do
Psychiatric
Psychiatric manifestations are common in DLBāpredominantly visual hallucinations, delusions, apathy, and anxiety. They are generally present early in the course of illness and may be the initial reason for referral. They also tend to persist; for example, hallucinations were stable in a placebo-treated DLB group over 20 weeks13 and in a cohort in which the disorder took its natural course over 52 weeks.41 The hallucinations are similar to those reported in PDD in that they are vivid, colourful,
Neurological
Extrapyramidal signs are reported in 25ā50% of patients with DLB at diagnosis, and most develop some such signs during the natural course. In up to 25% of autopsy-confirmed cases, however, there may be no record of extrapyramidal signs, which shows that parkinsonism is not necessary for clinical diagnosis of DLB. Indeed, the main reason for āmissingā DLB clinically in a prospective clinicopathological study was the absence of extrapyramidal signs.16 The next most common reason for missing the
Sleep
Rapid-eye-movement (REM) sleep behaviour disorder is a parasomnia manifested by vivid and frightening dreams associated with simple or complex motor behaviour during REM sleep. The disorder is frequently associated with the synucleinopathies, DLB, Parkinson's disease, and multiple system atrophy, but it rarely occurs in amyloidopathies and tauopathies.52 The neuropsychological pattern of impairment in REM sleep behaviour disorder/dementia is similar to that reported in DLB and qualitatively
Autonomic failure
Autonomic abnormalities including orthostatic hypotension and carotid-sinus hypersensitivity are more common in patients with DLB than in those with Alzheimer's disease or in age-matched controls.57 Clinical presentation of DLB is commonly with ādizziness,ā presyncope, syncope, and falls,58, 59 and autonomic dysfunction is a risk factor for falls in 65% of these cases, through either orthostatic hypotension or carotid-sinus hypersensitivity. Urinary incontinence has been reported early in the
Disease progression and survival
There is conflicting evidence from comparative studies with Alzheimer's disease about both symptom progression and survival in DLB. Most data have been obtained retrospectively. The most parsimonious explanation from the available findings is that there is no difference in progression between DLB and Alzheimer's disease,61 but mean values from large studies could conceal disease heterogeneity, and some patients with DLB have a very rapid disease course.62, 63 The conclusion is that either there
Clinical diagnosis of DLB
DLB can initially present to general practitioners, geriatric psychiatrists, movement-disorder specialists, or emergency services. As with all dementias, accurate clinical diagnosis can only be made after a thorough clinical assessment including a detailed history (from the patient and an informant) and full mental-state, cognitive, and physical (including neurological) examinations.2 There should be particular emphasis on eliciting the core diagnostic features of fluctuating cognitive
Laboratory and neuroimaging investigations
Systemic and pharmacological causes of delirium need to be excluded. The standard EEG may show early slowing, epoch-by-epoch fluctuation, and transient temporal slow-wave activity.68, 69, 70 There are as yet no clinically applicable genotypic or CSF markers to support a diagnosis of DLB.71, 72, 73, 74, 75, 76, 77 There have been, however, sufficient studies to allow the conclusion that neuroimaging investigations can be helpful in supporting the clinical diagnosis. Changes associated with DLB
Pathophysiology of DLB
Consensus criteria for DLB include ubiquitin immunohistochemistry for Lewy-body identification2, 16 and staging into three categories (brainstem-predominant, limbic, or neocortical) depending on the numbers and distribution of Lewy bodies. The recently developed Ī±-synuclein immunohistochemistry is a better marker86, 87 that visualises more Lewy bodies and also shows previously under-recognised neuritic pathology, termed Lewy neurites (figure 3). Use of antibodies to Ī±-synuclein moves the
Management of DLB
A four-stage approach to the management of DLB has been described: accurate diagnosis; identification of target symptoms with patient and carer; non-pharmacological interventions; and pharmacological interventions.98 Target symptoms can include extrapyramidal motor features, cognitive impairment, neuropsychiatric features (including hallucinations, depression, sleep disorder, and associated behavioural disturbances), or autonomic dysfunction. Patients, carers, and clinicians can differ in their
Trial designs and regulatory issues
There are no treatments licensed for DLB. Regulatory authorities seem prepared to accept DLB as an indication for regulatory approval of a pharmacological treatment on condition that its existence is widely accepted by experts, that it can be operationally defined by reliable and valid criteria, and that outcomes for studies use validated and standardised outcome measures. The US Food and Drug Administration has considered DLB as an indication and initially has suggested that there be dual
Trial designs
Few DLB treatment trials have been reported, partly because the disorder was only recently described, but also because of restricted expertise in clinical diagnosis. The current approach is to address DLB and PDD separately, but the close relation of these disorders and the logistics of recruitment provide the opportunity for both populations of patients to enter into a single clinical trial with a harmonised set of entry criteria. Post-hoc subanalysis could be used to assess for differential
Outcome measures
Specific measures of attention and cognitive fluctuation, which are both part of the clinical profile of DLB and PDD, are sensitive to response to treatment intervention.109 Other key domains of executive functioning, visual perception, and memory systems must also be measured. The most important neuropsychiatric target symptoms include visual hallucinations, delusions, delusional misidentification, apathy, anxiety, and depression. The desired behavioural outcomes might be a reduction in both
Global awareness of DLB and educational and treatment needs
Most dementia research has been done in North America, Australia, and Europe, but even in these regions, awareness of DLB is only now becoming widespread within specialist care. In countries with less developed dementia services and with greater reliance on primary care, there are substantial difficulties in translating current methods of case detection and diagnosisāeg, administration of cognitive tests to patients who are illiterate or have little education. In most cultures, dementia has
Conclusions
DLB is one of a group of neurodegenerative disorders that has been characterised as the Ī±-synucleinopathies. The group includes Parkinson's disease with and without dementia and primary autonomic failure. Clinical criteria and assessment scales for the accurate diagnosis of DLB have been developed in the past decade, and these are useful in the differentiation of DLB from other dementia subtypes, particularly Alzheimer's disease and vascular cognitive impairment. But diagnostic accuracy of DLB
Search strategy and selection criteria
References (110)
- et al.
Vascular cognitive impairment
Lancet Neurol
(2003) - et al.
Neuroleptic sensitivity in dementia with Lewy bodies and Alzheimer's disease
Lancet
(1998) - et al.
Senile dementia of Lewy body type: a clinically and neuropathologically distinct form of Lewy body dementia in the elderly
J Neurol Sci
(1990) Dementia associated with Parkinson's disease
Lancet Neurol
(2003)- et al.
Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study
Lancet
(2000) - et al.
Reality monitoring and visual hallucinations in Parkinson's disease
Neuropsychologia
(2003) - et al.
Spectrum of Parkinson's disease, Parkinson's dementia, and Lewy body dementia
- et al.
The native form of alpha-synuclein is not found in the cerebrospinal fluid of patients with Parkinson's disease or normal controls
Neurosci Lett
(1998) - et al.
Altered expression of the synucelin family mRNA in Lewy body and Alzheimer's disease
Brain Res
(2001) - et al.
Lewy bodies contain altered alpha-synuclein in brains of many familial Alzheimer's disease patients with mutations in presenilin and amyloid precursor protein genes
Am J Pathol
(1998)
Neuroleptic sensitivity to risperidone in Lewy body dementia
Lancet
Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop
Neurology
Rivastigmine provides symptomatic benefit in dementia with Lewy bodies: findings from placebo-controlled international multicenter study
Neurology
Neuroleptic sensitivity in patients with senile dementia of Lewy body type
BMJ
Diffuse type of Lewy body disease: progressive dementia with abundant cortical Lewy bodies and senile changes of varying degree: a new disease?
Clin Neuropathol
Clinical and pathological features of diffuse cortical Lewy body disease (Lewy body dementia)
Brain
The Lewy body variant of Alzheimer's disease: a clinical and pathologic entity
Neurology
Dementia associated with cortical Lewy bodies: proposed diagnostic criteria
Dementia
Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment
Mov Disord
Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study
J Neurol Neurosurg Psychiatry
Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies
Am J Pathol
Prospective validation of consensus criteria for the diagnosis of dementia with Lewy bodies
Neurology
Sensitivity and specificity of three clinical criteria for dementia with Lewy bodies in an autopsy-verified sample
Int J Geriatr Psychiatry
Influence of Alzheimer pathology on clinical diagnostic accuracy in dementia with Lewy bodies
Neurology
Dementia with Lewy bodies: reliability and validity of clinical and pathologic criteria
Neurology
Accuracy of the clinical diagnoses of Lewy body disease, Parkinson's disease, and dementia with Lewy bodies
Arch Neurol
Validity of current clinical criteria for Alzheimer's disease, vascular dementia and dementia with Lewy bodies
Br J Psychiatry
Validity of clinical criteria for the diagnosis of dementia with Lewy bodies
Neurology
Accuracy of four clinical diagnostic criteria for the diagnosis of neurodegenerative dementias
Neurology
Diagnostic accuracy of dementia with Lewy bodies
Arch Neurol
Research evaluation and prospective diagnosis of dementia with Lewy bodies
Arch Neurol
SIC Task Force Appraisal of clinical diagnostic criteria for parkinsonian disorders
Mov Disord
Lewy bodies in Alzheimer's disease: a neuropathological review of 145 cases using alpha-synuclein immunohistochemistry
Brain Pathol
Fluctuations in attention: PD dementia vs DLB with parkinsonism
Neurology
A comparative study of psychiatric symptoms in dementia with Lewy bodies and Parkinson's disease with and without dementia
Int J Geriatr Psychiatry
Dementia with Lewy bodies according to the consensus criteria in a general population aged 75 years or older
J Neurol Neurosurg Psychiatry
What is the clinical prevalence of Lewy body dementia?
Int J Geriatr Psychiatry
Islington study of dementia subtypes in the community
Br J Psychiatry
Pathological correlates of lateāonset dementia in a multicentre, community-based population in England and Wales
Lancet
Neuropsychological aspects of Lewy body dementia
Semantic memory is impaired in both dementia with Lewy bodies and dementia of Alzheimer's type: a comparative neuropsychological study and literature review
J Neurol Neurosurg Psychiatry
Simple standardised neuropsychological assessments aid in the differential diagnosis of dementia with Lewy bodies from Alzheimer's disease and vascular dementia
Dement Geriatr Cogn Disord
Qualitative performance characteristics differentiate dementia with Lewy bodies and Alzheimer's disease
J Neurol Neurosurg Psychiatry
Neuropsychological performance in Lewy body dementia and Alzheimer's disease
Br J Psychiatry
The Clinician Assessment of Fluctuation and the One Day Fluctuation Assessment Scale: two methods to assess fluctuating confusion in dementia
Br J Psychiatry
Quantification and characterisation of fluctuating cognition in dementia with Lewy bodies and Alzheimer's disease
Dement Geriatr Cogn Disord
The natural history of psychosis and depression in dementia with Lewy bodies and Alzheimer's disease: persistence and new cases over 1 year of follow-up
J Clin Psychiatry
The Neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia
Neurology
Topography, extent, and clinical relevance of neurochemical deficits in dementia of Lewy body type, Parkinson's disease and Alzheimer's disease
Ann NY Acad Sci
Predicting response to rivastigmine in dementia with Lewy bodies
Eur Neuropsychopharmacol
Cited by (655)
Role of rafts in neurological disorders
2023, NeurologiaThe unique neuropathological vulnerability of the human brain to aging
2023, Ageing Research ReviewsIdentification of Potentially Repurposable Drugs for Lewy Body Dementia Using a Network-Based Approach
2024, Journal of Molecular Neuroscience